# US 8,277,799 B2 · Inhibition of pathogens by probiotic bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,799 B2
- Document ID: US8277799B2
- Status: Granted
- Kind: B2
- Application number: 12/756,658
- Filed: 2010-04-08
- Published: 2011-08-04
- Granted: 2012-10-02
- Earliest claimed: 1999-11-08
- Assignees: Ganeden Biotech, Inc.
- Inventors: Sean Farmer
- Web page: https://patentgrep.com/patent/US8277799B2

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- Y10S 435/832: Bacillus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

## Claims

### Claim 1

A method of maintaining gastrointestinal tract health comprising administering to the gastrointestinal tract of a mammal a composition comprising an isolated Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086), wherein said strain colonizes the gastrointestinal tract of said mammal to maintain gastrointestinal health.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition is administered orally, buccally, or nasally.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition is administered in a food or as a food supplement.

### Claim 4 (depends on 1)

The method of claim 1, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 25-35° C.

### Claim 5 (depends on 1)

The method of claim 1, wherein said strain produces lactic acid and has an optimal growth temperature of 30° C.

### Claim 6 (depends on 1)

The method of claim 1, wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

### Claim 7 (depends on 1)

The method of claim 1, wherein said composition comprises a viable Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086) vegetative bacterial cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein said composition comprises a viable Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086) bacterial spore.

### Claim 9 (depends on 1)

The method of claim 1, wherein said composition comprises 1×103 to 1×1014 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).

### Claim 10 (depends on 1)

The method of claim 1, wherein said composition comprises 1×108 to 1×1010 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).

### Claim 11 (depends on 1)

The method of claim 1, wherein said composition comprises 1×109 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).
